Catalog No.S8141

For research use only.

Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.

Cl-amidine Chemical Structure

CAS No. 1043444-18-3

Selleck's Cl-amidine has been cited by 13 publications

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
PAD1 [1]
(Cell-free assay)
PAD4 [1]
(Cell-free assay)
PAD3 [1]
(Cell-free assay)
0.8 μM 5.9 μM 6.2 μM
In vitro

Cl-amidine antagonizes the PAD4-mediated enhancement of the the p300GBD-GRIP1 interaction in a dose-dependent manner. The inhibitory effect of this compound is not a nonspecific one but is targeted at the active PAD4 enzyme[1]. Cl-amidine increases p53 expression in CD45 positive immune cells. It triggers the differentiation and apoptosis of multiple cancer cell lines that are p53+/+ and p53−/− (e.g., HL60, HT29, TK6, and U2-OS cells). Cl-amidine induces the expression of p53 and several downstream target genes including the cyclin dependent kinase inhibitor p21, GADD45, and the proapoptotic protein PUMA in U2-OS osteosarcoma cells[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 M1y4XmN6fG:2b4jpZ4l1gSCjc4PhfS=> NHzvcIg1ODBidV2= NXHiOJlmQTZiaILz MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygcpVu[mW{IHH0JFQxOCC3TTDh[pRmeiB7NjDodpMh[nlidIL5dIFvKGKudXWgZZN{[Xl? MnHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MkC2NlQoRjJ|NEKwOlI1RC:jPh?=
MDA-MB-231 MYLDfZRwfG:6aXPpeJkh[XO|YYm= NVrIdnI6OjByIITvJFQxOCC3TR?= MkTTPVYhcHK| MljaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBifCB{MECgeI8hPDByIIXNJIFnfGW{IEm2JIhzeyCkeTD0dplx[W5iYnz1[UBie3OjeR?= NH;EeFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SyNFYzPCd-MkO0NlA3OjR:L3G+
HL60 M2\OdWZ2dmO2aX;uJIF{e2G7 MXi1JJRwKDFyIIXN Mo[5NVUhdWmwcx?= NICwNnVKdmirYnn0bY9vKG:oIGDBSFQhcW5iaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSTJ|MUi3MYlv\HWlZXSgZ4l1enWubHnuZZRm\CCKNDDs[ZZmdCCjdDC1JJRwKDFyIIXNJJBz\WmwY4XiZZRm\CCob4KgNVUhdWmwczDmc4xtd3enZDDifUBCOjNzOEegZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NYDBUlFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFQ6ODlpPkOwN|Q1QTB7PD;hQi=>
HEK293T MmLjSpVv[3Srb36gZZN{[Xl? MneyNVAhdk1idH:gNVAxKHWP NH7kW3ZKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDBSFMh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[XO|ZYPz[YQh[XNiY3;ueoVze2mxbjDv[kBDSUWHIITvJJNw\Gm3bTDi[Y57d3muLVytZ4l1enWubHnu[UBifCBzMDDuUUB1dyBzMECgeW0h[nliY3;sc5JqdWW2cnnjJIFv[Wy7c3nz M{S2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE6PjJ|NkGvK|5EcEWPQly8M4E,
HEK293T NXvsWYJZTnWwY4Tpc44h[XO|YYm= NUjQT4c1OTByIIXN MmLmNlQhcHK| NYPSbJdNUW6qaXLpeIlwdiCxZjD0bIFxe2mpYYLnbY4ucW6mdXPl[EBk\WyuIHTlZZRpKGmwIHj1cYFvKEiHS{K5N3Qh[2WubIOgc5ZmemW6cILld5NqdmdiaIXtZY4hemWlb33ibY5idnRiUFHEN{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDj[YxtKHO3co\peoFtKGG2IEGwNEB2VSC2cnXheIVlKDF3IH3pcpMheHKrb4KgeI8hfGijcIPp[4Fz\2mwIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BlenWpIITy[YF1dWWwdDDifUBu\XSqeXzlcoUh[my3 MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPVYzOzZzLze+R4hGVUKOPD;hQi=>
Methods Test Index PMID
Western blot PAD4 / H3R17Me / H3Cit / p21 / p53 / p-p53 ; iNOS ; MMP-2 / MMP-9 ; p-Elk-1 / Elk-1 18505818 29077055 28844713 21655091
In vivo Cl-amidine treatment inhibits NZM(New Zealand mixed 2328) NET(neutrophil extracellular trap) formation in vivo and significantly alters circulating autoantibody profiles and complement levels while reducing glomerular IgG deposition. Further, Cl-amidine increases the differentiation capacity of bone marrow endothelial progenitor cells, improves endothelium-dependent vasorelaxation, and markedly delays time to arterial thrombosis induced by photochemical injury. Cl-amidine delays thrombosis development in NZM mice. It inhibits PADs in mice without significant toxicity and improves disease phenotypes in animal models of inflammatory arthritis and inflammatory bowel disease[3]. And It is shown to reduce disease severity in mouse models of ulcerative colitis and RA[2].

Protocol (from reference)

Cell Research:


  • Cell lines: CV-1 cells
  • Concentrations: 0-200 μM
  • Incubation Time: 40 h
  • Method:

    CV-1 cells are transiently transfected with plasmids encoding a luciferase reporter construct, p300GBD fused to the Gal4 DNA binding domain, the p300 binding domain of GRIP1 (i.e., the AD1 domain) fused to the VP16 activation domain (AD), and either wild-type PAD4 or the catalytically defective C645S mutant. Cl-amidine (0-200 μM) is then added to the cell culture medium and incubated for 40 h. Cell extracts are then prepared, and the luciferase activity present in these extracts is quantified. 

Animal Research:


  • Animal Models: DSS mouse model of colitis (genetic background:C57BL/6 mice)
  • Dosages: 75 mg/kg (i.p); 5, 25, and 75 mg/kg(oral)
  • Administration: by oral gavage or i.p

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 424.8


CAS No. 1043444-18-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C(C=C1)C(=O)NC(CCCN=C(CCl)N)C(=O)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cl-amidine | Cl-amidine supplier | purchase Cl-amidine | Cl-amidine cost | Cl-amidine manufacturer | order Cl-amidine | Cl-amidine distributor